Evidence map›Paper›PMID 27302680›Full record

ArticleExperimental neurology2016

Targeting Kv1.3 channels to reduce white matter pathology after traumatic brain injury.

Thomas M Reeves, Patricia A Trimmer, Beverly S Colley, Linda L Phillips

Abstract read
In one paragraph

Article in Experimental neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Dimethyl fumarate improves white matter function following severe hypoperfusion: Involvement of microglia/macrophages and inflammatory mediators.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thomas M ReevesDepartment of Anatomy and Neurobiology, School of Medicine, Virginia Commonwealth University Medical Center, Richmond, VA 23298, United States.
Patricia A TrimmerDepartment of Anatomy and Neurobiology, School of Medicine, Virginia Commonwealth University Medical Center, Richmond, VA 23298, United States.
Beverly S ColleyDepartment of Anatomy and Neurobiology, School of Medicine, Virginia Commonwealth University Medical Center, Richmond, VA 23298, United States.
Linda L PhillipsDepartment of Anatomy and Neurobiology, School of Medicine, Virginia Commonwealth University Medical Center, Richmond, VA 23298, United States.

Funding

Extracellular Matrix Mediates Axonal Integrity Following Brain TraumaR01NS056247 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI PHILLIPS, LINDA L. · 2007 to 2017
$3.4M
New Approaches to Axonal Protection After TBIR01NS057758 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI REEVES, THOMAS M. · 2007 to 2017
$3.3M
NINDS NIH HHS R01 NS056247NINDS NIH HHS R01 NS057758
6 · The paper itself

Abstract

Axonal injury is present in essentially all clinically significant cases of traumatic brain injury (TBI). While no effective treatment has been identified to date, experimental TBI models have shown promising axonal protection using immunosuppressants FK506 and Cyclosporine-A, with treatment benefits attributed to calcineurin inhibition or protection of mitochondrial function. However, growing evidence suggests neuroprotective efficacy of these compounds may also involve direct modulation of ion channels, and in particular Kv1.3. The present study tested whether blockade of Kv1.3 channels, using Clofazimine (CFZ), would alleviate TBI-induced white matter pathology in rodents. Postinjury CFZ administration prevented suppression of compound action potential (CAP) amplitude in the corpus callosum of adult rats following midline fluid percussion TBI, with injury and treatment effects primarily expressed in unmyelinated CAPs. Kv1.3 protein levels in callosal tissue extracts were significantly reduced postinjury, but this loss was prevented by CFZ treatment. In parallel, CFZ also attenuated the injury-induced elevation in pro-inflammatory cytokine IL1-β. The effects of CFZ on glial function were further studied using mixed microglia/astrocyte cell cultures derived from P3-5 mouse corpus callosum. Cultures of callosal glia challenged with lipopolysaccharide exhibited a dramatic increase in IL1-β levels, accompanied by reactive morphological changes in microglia, both of which were attenuated by CFZ treatment. These results support a cell specific role for Kv1.3 signaling in white matter pathology after TBI, and suggest a treatment approach based on the blockade of these channels. This therapeutic strategy may be especially efficacious for normalizing neuro-glial interactions affecting unmyelinated axons after TBI.

Indexed as

Action PotentialsAnimalsAnimals, NewbornBrain Injuries, TraumaticCalcium-Binding ProteinsCells, CulturedClofazimineCorpus CallosumCyclosporineDisease Models, AnimalElectric StimulationGene Expression RegulationImmunosuppressive AgentsKv1.3 Potassium ChannelLeukoencephalopathiesMaleAif1 protein, ratCalcium-Binding ProteinsClofazimineCyclosporineImmunosuppressive AgentsKv1.3 Potassium ChannelMicrofilament ProteinsPotassium Channel BlockersTacrolimusCompound action potentialsGlial cell cultureInflammationMicrogliaRecovery of functionWhite matter injury

Identifiers

PMID27302680
PMCPMC4992637

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.